Peter B. Davis is Director at NABI BIOPHARMACEUTICALS (NABI). They have made 2 open-market trades across 1 company since 2009, most recently 2010-05-20.
CIK 0001222789
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $35K since 2009, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NABI | 14,630 | — |
Shares reported on the most recent Form 4, priced at the 2010-05-24 close. 1 holding could not be priced and is excluded from the total.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.